Trade Novavax Inc - NVAX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.14 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 6.14 |
| Open | 6.11 |
| 1-Year Change | 59.53% |
| Day's Range | 5.77 - 6.2 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 5.92 | -0.27 | -4.36% | 6.19 | 6.28 | 5.77 |
| Apr 16, 2025 | 6.11 | 0.14 | 2.35% | 5.97 | 6.32 | 5.97 |
| Apr 15, 2025 | 6.24 | -0.06 | -0.95% | 6.30 | 6.54 | 6.02 |
| Apr 14, 2025 | 6.22 | 0.38 | 6.51% | 5.84 | 6.38 | 5.83 |
| Apr 11, 2025 | 5.78 | 0.40 | 7.43% | 5.38 | 5.88 | 5.19 |
| Apr 10, 2025 | 5.37 | -1.24 | -18.76% | 6.61 | 6.61 | 4.97 |
| Apr 9, 2025 | 6.67 | 0.52 | 8.46% | 6.15 | 6.94 | 5.91 |
| Apr 8, 2025 | 6.12 | -0.39 | -5.99% | 6.51 | 6.78 | 6.03 |
| Apr 7, 2025 | 6.49 | 0.68 | 11.70% | 5.81 | 6.56 | 5.60 |
| Apr 4, 2025 | 6.17 | 0.62 | 11.17% | 5.55 | 6.27 | 5.22 |
| Apr 3, 2025 | 5.57 | -0.12 | -2.11% | 5.69 | 5.78 | 5.31 |
| Apr 2, 2025 | 5.82 | -0.17 | -2.84% | 5.99 | 6.18 | 5.65 |
| Apr 1, 2025 | 5.99 | -0.32 | -5.07% | 6.31 | 6.43 | 5.95 |
| Mar 31, 2025 | 6.34 | -0.61 | -8.78% | 6.95 | 6.95 | 5.97 |
| Mar 28, 2025 | 6.97 | -0.28 | -3.86% | 7.25 | 7.32 | 6.89 |
| Mar 27, 2025 | 7.23 | -0.13 | -1.77% | 7.36 | 7.44 | 7.19 |
| Mar 26, 2025 | 7.37 | -0.16 | -2.12% | 7.53 | 7.53 | 7.21 |
| Mar 25, 2025 | 7.54 | -0.12 | -1.57% | 7.66 | 7.67 | 7.44 |
| Mar 24, 2025 | 7.66 | 0.12 | 1.59% | 7.54 | 7.76 | 7.54 |
| Mar 21, 2025 | 7.57 | 0.03 | 0.40% | 7.54 | 7.63 | 7.42 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Novavax Company profile
Novavax Inc. (NVAX) is a biotechnology company that specialises in the discovery, development and commercialisation of innovative vaccines that prevent serious infectious diseases.
Headquartered in Maryland, United States, the company was founded in 1987.
It has developed a number of vaccines, including:
The Coronavirus vaccine NVX-CoV2373, currently in phase 3 trials.
The seasonal Influenza vaccine NanoFlu™ for adults over the age of 65, currently also in phase 3 trials.
The respiratory Syncytial Virus (RSV) vaccine ResVax™ for infants and maternal immunisation, currently in phase 3 trials, as well as two RSV F Vaccines, one for older adults (phase 2 trials) and one for children until the age of 5 (phase 1 trials).
The Ebola Virus vaccine Ebola GP Vaccine, currently in phase 1 trials.
The company develops its vaccines using genetically engineered three-dimensional nanostructures of recombinant proteins that are critical to disease pathogenesis.
The company is also working on producing immune-stimulating adjuvants at its wholly owned Swedish subsidiary Novavax AB.
Navavax’s key partners and collaborators include:
The Coalition for Epidemic Preparedness Innovations (CEPI), which has been funding the company to develop and manufacture its coronavirus vaccine candidate.
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
The Serum Institute of India (SII).
The 2009 joint venture with India’s privately held pharmaceutical company, Cadila Pharmaceuticals Ltd, to develop Novavax VLP vaccine candidates and some Cadila therapeutic vaccine candidates.
The company (ticker: NVAX) went public on the NASDAQ stock exchange in 1995.
| Industry: | Biotechnology & Medical Research (NEC) |
700 Quince Orchard Road
GAITHERSBURG
MARYLAND 20878
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com